Skip to Content

Are you based in North America? If yes, switch to our North American website →

IGH/BCL2 Translocation, Dual Fusion

Applications
haematopathology
Catalogue Numbers
LPS 033 (10 tests)
LPS 033-S (5 tests)

The IGH/BCL2 fusion gene is brought about by a t(14;18)(q32;q21) translocation and is found in over 88% of follicular lymphoma cases1,2.

The translocation is thought to be brought about by an error in the joining function of the IGH gene, mediated by the recent observation that both IGH and BCL2 are arranged next to each other in 3D space in the normal B lymphocytes2. The translocation breakpoint at the end of the Joining (J) segment, and the subsequent fusion of the BCL2 gene to this region, results in the BCL2 gene coming under the regulatory control of those processes normally involved in maintenance of IGH gene activity3

The BCL2 gene itself has been shown to be involved in the regulation of apoptosis4.

References

1. Bernicot et al., Cytogenet Genome Res. 2007;118(2-4):345-52

2. Roix et al., Nature Genetics 2003;34(3):287-91

3. Stoos-Veić et al., Coll Antropol. 2010 Jun;34(2):425-9

4. Sharpe et al., Biochim Biophys Acta. 20041644(2-3):107-13

Microscope Images

IGH BCL2 Translocation Dual Fusion magnified
Area of Interest*
Lymphoma

Disclaimer

This product is intended to be used on Carnoy’s solution (3:1 methanol/acetic acid) fixed haematological samples, or formalin-fixed paraffin-embedded (FFPE) tissues.

*Disease information supported by the literature and is not a reflection of the intended purpose of this product.